27858708|t|Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia.
27858708|a|BACKGROUND: Primary progressive aphasia (PPA) may present with three main clinical variants, namely nonfluent agrammatic (nfaPPA), semantic (sPPA), and logopenic (lPPA) subtypes. Frontotemporal lobar degenerations (FTLD) or Alzheimer's disease (AD) are the most common etiologies. OBJECTIVE: To study the potential of cerebrospinal fluid (CSF) biomarkers for identifying the underlying pathology in patients with PPA. METHODS: CSF levels of total tau protein (tauT), amyloid-beta peptide (Abeta42), and tau phosphorylated at threonine-181 (tauP - 181) were measured by double sandwich, enzyme-linked immunosorbent assay (ELISA) in 43 patients with PPA, 26 patients with AD, and 17 healthy controls. RESULTS: All patients could be classified as compatible with the AD or non-AD biomarker profile, either with the three biomarkers (90.7%) or their ratios, especially the tauP - 181/Abeta42 ratio (9.3%). An AD-compatible biomarker profile was present in 39.5% of all PPA patients, specifically 22.2%, 35.7%, and 75% of nfaPPA, sPPA, and lPPA, respectively. In PPA patients with a non-AD profile (presumably FTLD), two different clusters could be identified according to the tauP - 181/tauT ratio, possibly corresponding to the two major FTLD pathologies (tau and TDP-43). CONCLUSION: CSF biomarkers may be a valuable tool for the discrimination between PPA patients with AD and non-AD pathophysiology and possibly between FTLD patients with tau and TDP-43 pathology.
27858708	83	110	Primary Progressive Aphasia	Disease	MESH:D018888
27858708	124	151	Primary progressive aphasia	Disease	MESH:D018888
27858708	153	156	PPA	Disease	MESH:D018888
27858708	275	279	lPPA	Disease	
27858708	291	325	Frontotemporal lobar degenerations	Disease	MESH:D057174
27858708	327	331	FTLD	Disease	MESH:D057174
27858708	336	355	Alzheimer's disease	Disease	MESH:D000544
27858708	357	359	AD	Disease	MESH:D000544
27858708	511	519	patients	Species	9606
27858708	525	528	PPA	Disease	MESH:D018888
27858708	559	562	tau	Gene	4137
27858708	601	608	Abeta42	Gene	351
27858708	615	618	tau	Gene	4137
27858708	746	754	patients	Species	9606
27858708	760	763	PPA	Disease	MESH:D018888
27858708	768	776	patients	Species	9606
27858708	782	784	AD	Disease	MESH:D000544
27858708	824	832	patients	Species	9606
27858708	876	878	AD	Disease	MESH:D000544
27858708	886	888	AD	Disease	MESH:D000544
27858708	992	999	Abeta42	Gene	351
27858708	1017	1019	AD	Disease	MESH:D000544
27858708	1077	1080	PPA	Disease	MESH:D018888
27858708	1081	1089	patients	Species	9606
27858708	1147	1151	lPPA	Disease	
27858708	1170	1173	PPA	Disease	MESH:D018888
27858708	1174	1182	patients	Species	9606
27858708	1194	1196	AD	Disease	MESH:D000544
27858708	1217	1221	FTLD	Disease	MESH:D057174
27858708	1347	1351	FTLD	Disease	MESH:D057174
27858708	1365	1368	tau	Gene	4137
27858708	1373	1379	TDP-43	Gene	23435
27858708	1463	1466	PPA	Disease	MESH:D018888
27858708	1467	1475	patients	Species	9606
27858708	1481	1483	AD	Disease	MESH:D000544
27858708	1492	1494	AD	Disease	MESH:D000544
27858708	1532	1536	FTLD	Disease	MESH:D057174
27858708	1537	1545	patients	Species	9606
27858708	1551	1554	tau	Gene	4137
27858708	1559	1565	TDP-43	Gene	23435
27858708	Association	MESH:D057174	4137
27858708	Association	MESH:D057174	23435
27858708	Association	MESH:D018888	4137
27858708	Association	MESH:D018888	23435
27858708	Association	MESH:D018888	351

